<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02074241</url>
  </required_header>
  <id_info>
    <org_study_id>2012XLC02-2</org_study_id>
    <secondary_id>2012XLC02</secondary_id>
    <nct_id>NCT02074241</nct_id>
  </id_info>
  <brief_title>Molecular Markers of Chemosensitivity for Bladder Cancer</brief_title>
  <official_title>Molecular Markers of Chemosensitivity for Locally Advanced, Recurrent and Metastatic Bladder Cancer Based on the Adjuvant Chemotherapy of Gemcitabine and Cisplatin-a Prospective Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southwest Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to try to figure out some bio-markers of chemosensitivity for
      adjuvant chemotherapy for bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Figure out some bio-markers of chemosensitivity for adjuvant chemotherapy for bladder cancer.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cancer progressive free survival rate</measure>
    <time_frame>60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Effects of Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Positive Expression</arm_group_label>
    <description>Expression analysis:Positive expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51,SNF5, etc) in bladder cancer specimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative Expression</arm_group_label>
    <description>Expression analysis:Negative expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51, SNF5,etc) in bladder cancer specimens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Expression analysis</intervention_name>
    <description>Analysis of the expression of DNA repair genes (XPC, XPF, Brca1, Rad51,SNF5, etc.) in bladder cancer specimens.</description>
    <arm_group_label>Positive Expression</arm_group_label>
    <arm_group_label>Negative Expression</arm_group_label>
    <other_name>E-A</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      bladder cancer specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. The patients of locally advanced, recurrent, metastatic transitional cell carcinoma.

          2. Gone through standardize radical cystectomy and pelvic lymphadenectomy or inoperable.

          3. Experienced adjuvant chemotherapy(Gemcitabine and Cisplatin).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18 years of age or older, estimated life expectancy ≥ 6 months.

          2. .Gone through standardize radical cystectomy and pelvic lymphadenectomy or inoperable.

          3. Transitional cell carcinoma of bladder, stage pT3N0M0,T2N1M0-T3-4N1-2M1.Transitional
             cell carcinoma may be with or without squamous cell carcinoma and/or adenocarcinoma
             components.

          4. Electrocorticography(ECOG) performance status 0-2.

          5. Blood routine:Absolute neutrophil count (ANC) ≥ 1500/μL,White blood cell count ≥
             3000/μLPlatelets ≥ 100,000/μL,Hemoglobin ≥ 10.0 g/dL,

          6. Total serum bilirubin≤ 1.5 x upper limit of normal (ULN).Serum aspartate transaminase
             (AST; serum glutamic oxaloacetic transaminase(SGOT)) and serum alanine transaminase
             (ALT; serum glutamic pyruvic transaminase (SGPT)) ≤ 2.5 x upper limit of normal (ULN).

          7. Creatinine clearance rate,Ccr ≥ 60%

          8. ECG：no arrhythmias, no myocardial infarction. Signed and dated informed consent
             document indicating that the patient (or legally acceptable representative) has been
             informed of all pertinent aspects of the trial prior to enrollment.

        Willingness and ability to comply with scheduled visits, treatment plans, laboratory
        tests,and other study procedures.

        Exclusion Criteria:

          1. Past history of systemic chemotherapy

          2. Serious heart and lung dysfunction.

          3. Associated with central or peripheral neuropathy greater than 2 grade.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiwen Chen, M.D,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Hospital, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest hospital,Chian</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2014</study_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Hospital, China</investigator_affiliation>
    <investigator_full_name>Zhiwen Chen</investigator_full_name>
    <investigator_title>M.D,Ph.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

